Europe Antiplatelet Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drug Class, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Europe Antiplatelet Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drug Class, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

The Europe Antiplatelet Market would witness market growth of 4.5% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 105.4 million Units, showcasing a growth of 3.3% (2019-2022).

The accessibility and availability of the healthcare infrastructure also influence the demand for antiplatelet medications. In addition, several nations have developed healthcare systems with modern hospitals, pharmacies, and other healthcare facilities that can detect and treat cardiovascular illnesses better. Access to adequate healthcare services enables patients to receive appropriate prescriptions and follow-up care, driving the demand for antiplatelet medications. The increasing geriatric population also contributes to market expansion. Due to the increased risk of cardiovascular disease and its complications in older persons, there is a higher demand for antiplatelet medications to prevent thrombotic events, which is anticipated to support the expansion of the antiplatelet market. The market growth is expected to be driven by high growth potential in untapped, emerging markets due to improved healthcare infrastructure, rising unmet healthcare needs, and increasing prevalence of cardiovascular diseases.

To support the market expansion, pharmaceutical companies are spending on research and development to create new and enhanced antiplatelet drugs. Furthermore, introducing more potent antiplatelet agents, like P2Y12 receptor inhibitors such as prasugrel and ticagrelor, has afforded clinicians a greater variety of treatment options. Continuous innovation and the development of newer, more effective antiplatelet pharmaceuticals contribute to the expansion of the market. The demand for better healthcare services is increasing, the government is making significant investments to upgrade the healthcare infrastructure, and the medical industry is developing rapidly in emerging economies, supporting market growth. As a result, the healthcare industry in emerging economies is also expanding significantly.

According to Government of UK, the average age surpassed 40 for the first time in the middle of 2014. By 2040, nearly one in seven individuals will be over 75. It is anticipated that 1.42 million more households will be headed by someone aged 85 or older by 2037, a 161% increase over 25 years. The proportion of the working-age population between the ages of 50 and the state pension age is expected to rise from 26% in 2012 to 34% in 2050, a rise of over 5.5 million people. Aging is a well-established risk factor for cardiovascular diseases (CVDs), including coronary artery disease, stroke, and peripheral artery disease. Therefore, the region presents lucrative growth prospects for the market in the coming years.

The Germany market dominated the Europe Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $343.9 Million by 2030. The UK market is exhibiting a CAGR of 3.6% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.2% during (2023 - 2030).

Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration (Volume, million Units, USD Million, 2019-2030)

• Oral
• Injectable

By Drug Class (Volume, million Units, USD Million, 2019-2030)

• Adenosine diphosphate (ADP) Receptor Inhibitors
• Irreversible Inhibitors Cyclooxygenase
• Others

By Distribution Channel (Volume, million Units, USD Million, 2019-2030)

• Drug store & Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Country (Volume, Million Units, USD Million, 2019-2030)

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Cipla Limited
• Glenmark Pharmaceuticals Limited
• Bayer AG
• AstraZeneca PLC
• Daiichi Sankyo Company, Limited
• Eli Lilly And Company
• Otsuka Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Lupin Limited
• Chiesi Farmaceutici S.p.A

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free